Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.

2.

Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim.

Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, Hunt AE, Evan GI, Broaddus VC.

Mol Cancer Ther. 2007 Oct;6(10):2766-76.

3.

Targeting the mTOR signaling network in cancer.

Chiang GG, Abraham RT.

Trends Mol Med. 2007 Oct;13(10):433-42. Epub 2007 Oct 1. Review.

PMID:
17905659
4.

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.

Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT.

Mol Cancer Ther. 2007 Sep;6(9):2505-14. Epub 2007 Aug 31.

5.

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.

Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M.

Clin Cancer Res. 2007 Aug 15;13(16):4795-9.

6.

The third dimension bridges the gap between cell culture and live tissue.

Pampaloni F, Reynaud EG, Stelzer EH.

Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45. Review.

PMID:
17684528
7.

Defining the role of mTOR in cancer.

Guertin DA, Sabatini DM.

Cancer Cell. 2007 Jul;12(1):9-22. Review.

8.

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.

Abraham RT, Gibbons JJ.

Clin Cancer Res. 2007 Jun 1;13(11):3109-14. Review.

9.

Malignant pleural mesothelioma: current concepts in treatment.

Tsiouris A, Walesby RK.

Nat Clin Pract Oncol. 2007 Jun;4(6):344-52. Review.

PMID:
17534390
10.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

11.

Life isn't flat: taking cancer biology to the next dimension.

Smalley KS, Lioni M, Herlyn M.

In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):242-7. Review.

PMID:
17163781
12.

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J.

Cancer Cell. 2006 Nov;10(5):425-35. Erratum in: Cancer Cell. 2009 Nov 6;16(5):448.

13.

Stress and mTORture signaling.

Reiling JH, Sabatini DM.

Oncogene. 2006 Oct 16;25(48):6373-83. Review.

PMID:
17041623
14.

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.

Naumov GN, Akslen LA, Folkman J.

Cell Cycle. 2006 Aug;5(16):1779-87. Epub 2006 Aug 15. Review.

PMID:
16931911
15.

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Weinstein IB, Joe AK.

Nat Clin Pract Oncol. 2006 Aug;3(8):448-57. Review.

PMID:
16894390
16.

Drug penetration in solid tumours.

Minchinton AI, Tannock IF.

Nat Rev Cancer. 2006 Aug;6(8):583-92. Review.

PMID:
16862189
17.

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM.

Cell. 2006 May 19;125(4):733-47. Epub 2006 Apr 27.

18.

Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

Garcia-Carbonero R, Paz-Ares L.

Eur J Surg Oncol. 2006 Aug;32(6):676-81. Epub 2006 Apr 17. Review.

PMID:
16616827
19.

TOR signaling in growth and metabolism.

Wullschleger S, Loewith R, Hall MN.

Cell. 2006 Feb 10;124(3):471-84. Review.

20.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.

Cancer Res. 2006 Feb 1;66(3):1500-8.

Supplemental Content

Support Center